

INFORMATION DISCLOSURE STATEMENT


Applicant : Goddard, et al. (as amended)
App. No : 10/063,519
Filed : May 1, 2002
For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME
Examiner : Larry Ronald Helms
Art Unit : 1642

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 29, 2005

(Date)



Daniel Hart, Reg. No. 40,637

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing thirty-two (32) references to be considered by the Examiner. Also enclosed are nineteen (19) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 29, 2005

By: Daniel Hart

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 30,313

(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/063,519
	Filing Date	May 1, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1642
	Examiner	Larry Ronald Helms
SHEET 1 OF 2	Attorney Docket No.	GNE.3230R1C11

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, Dean	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582 B1	05-08-2001	Rodier, et al.	
	6	6,395,306 B1	05-28-2002	Cui, et al.	
	7	6,414,117 B1	07-02-2002	Levinson, D. A.	
	8	6,465,185 B1	10-15-2002	Goldfine, et al.	
	9	6,498,235 B2	12-24-2002	Sheppard, et al.	
	10	6,562,343 B1	05-13-2003	Levinson, D. A.	
	11	6,645,499 B1	11-11-2003	Lal, et al.	
	12	6,730,502 B2	05-04-2004	Van Hijum, et al.	
	13	6,737,522 B2	05-18-2004	Sundick, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/063,519
	Filing Date	May 1, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1642
	Examiner	Larry Ronald Helms
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C11

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	16	The 1991 Boehringer Mannheim Biochemicals Catalog, page 557, 1991.	
	17	BURGESS, et al. 1990. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. <i>The Journal of Cell Biology</i> , 111:2129-2138.	
	18	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	19	GYGI, et al. 1999. Correlation between protein and mRNA abundance in yeast. <i>Molecular and Cellular Biology</i> , 19(3):1720-1730.	
	20	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	21	LAZAR, et al. 1988. Transforming growth factor α : Mutation of aspartic acid 47 and leucine 48 results in different biological activities. <i>Molecular and Cellular Biology</i> , 8(3):1247-1252.	
	22	LEWIN, B. 1994. Oncogenes: Gene expression and cancer, Chap. 39, pp. 1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	23	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	24	LIN, et al. 1975. Structure-function relationships in glucagon: Properties of highly purified Des-His ¹ -, Monoiodo-, and [Des-Asn ²⁸ , Thr ²⁹](homoserine lactone ²⁷)-glucagon. <i>Biochemistry</i> , 14(8):1559-1563.	
	25	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	26	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	27	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu.</i> , 1(27):165-190.	
	28	SCHWARTZ, et al. 1987. A superactive insulin: [B10-aspartic acid]insulin(human). <i>Proc. Natl. Acad. Sci. USA</i> , 84:6408-6411.	
	29	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	
	30	2002-2003 Catalog & Technical Reference, New England BioLabs, Inc., p. 122.	
	31	Database Search, DNA Sequence Alignments [BLASTN 2.2.1[July-12-2001], NCBI].	
	32	Database Search, Protein Sequence Alignments [BLASTN 2.2.1[July-12-2001], NCBI].	

1687958_1:dmb
042905

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.